What is Endocrinology: Pathophysiology to Therapy (2024)?
Endocrinology: Pathophysiology to Therapy is a 2024 first-edition textbook by Akuffo Quarde that connects endocrine physiology with the mechanisms of medical therapies. It covers pituitary, thyroid, adrenal, pancreatic, parathyroid, reproductive, lipid, obesity, and diagnostic topics, making it relevant to endocrinology trainees and other healthcare professionals.
Introduction
Understanding endocrinology requires more than memorizing hormone pathways, drug names, and treatment options. The most useful clinical knowledge comes from understanding why a therapy works, which physiological pathway it affects, and what consequences may follow from modifying that pathway.
That principle is central to Endocrinology: Pathophysiology to Therapy, a first-edition textbook by Akuffo Quarde, MD, published in 2024 by John Wiley & Sons Ltd./Wiley-Blackwell. The book is designed around an integrated approach in which relevant endocrine physiology is presented before the mechanisms of selected medical interventions are discussed.
Rather than attempting to function primarily as a guideline manual, the book emphasizes the pathophysiological basis of endocrine therapies. Its stated purpose is to help readers understand the rationale behind treatment choices and appreciate complex endocrine concepts in a clinically relevant way.
This approach makes the book particularly relevant to endocrinology fellows, practicing physicians, internal medicine residents, medical students, pharmacists, nurse practitioners, physician assistants, and other healthcare professionals. The author also emphasizes the importance of landmark clinical trials and includes selected practice-changing trials where relevant.
The specialty coverage is broad. Across nine chapters and supporting appendices, the book moves from pituitary therapies through thyroid, adrenal, pancreatic, parathyroid and bone, reproductive, lipid and obesity disorders, additional endocrine topics, and finally dynamic testing in clinical endocrinology.
Book Overview
|
Detail |
Information |
|
Full
title |
Endocrinology: Pathophysiology to
Therapy |
|
Edition |
First Edition |
|
Author |
Akuffo Quarde, MD |
|
Publisher |
John Wiley & Sons Ltd /
Wiley-Blackwell |
|
Publication
year |
2024 |
|
Medical
specialty |
Endocrinology |
|
Primary
focus |
Endocrine physiology,
pathophysiology, mechanisms of therapy, clinical pharmacology, and dynamic
testing |
|
Intended
audience |
Endocrinology fellows, physicians,
internal medicine residents, medical students, pharmacists, nurse
practitioners, physician assistants, and other allied healthcare
professionals |
The bibliographic information identifies Akuffo Quarde as the author and describes the publication as a 2024 Wiley-Blackwell title. The listed subjects include endocrine-system diseases, endocrine-gland pathophysiology, and endocrine-system therapy.
The author is identified as a clinical instructor at the University of Minnesota Medical School and as working in an endocrinology, diabetes, and metabolism clinic at Sanford Health in Bemidji, Minnesota, USA.
WHAT THIS BOOK COVERS
1. Pituitary Gland Therapies
The opening chapter focuses on therapeutic approaches to pituitary-related disorders. It begins with Cushing’s disease, discussing therapies including pasireotide, retinoic acid, dopaminergic agonists, steroidogenesis inhibitors, and mifepristone.
A recurring structure is immediately apparent: physiology is introduced, followed by the mechanism of action and then a practical guide. For example, the discussion of pasireotide explains the hypothalamic–pituitary–adrenal axis and the role of somatostatin receptor subtypes before examining the drug's mechanism and clinical considerations.
The chapter also covers:
- Acromegaly
- Prolactinoma
- Adult growth hormone insufficiency
- Central diabetes insipidus
- Syndrome of inappropriate ADH secretion
- Practice-based questions
- References
Therapeutic classes and interventions include somatostatin analogs, growth hormone receptor antagonists, dopaminergic agonists, growth hormone, desmopressin, vaptans, water restriction, and other approaches.
2. Thyroid Gland Therapies
Chapter 2 addresses a wide range of thyroid disorders and their treatments.
The chapter includes:
- Hashimoto’s thyroiditis
- Graves’ disease
- Thyroid eye disease
- Riedel’s thyroiditis
- Thyroid hormone resistance
- TSH-secreting tumors
- Thyroid cancer
Therapies discussed include levothyroxine, liothyronine, selenium, thionamides, Lugol’s iodine, iodide transport inhibitors, glucocorticoids, beta-blockers, cholestyramine, lithium, teprotumumab, rituximab, somatostatin receptor ligands, tyrosine kinase inhibitors, radioactive iodine ablation, and mTOR inhibitors.
This section illustrates one of the book's defining characteristics: medications are not simply listed as treatment options. The contents indicate a repeated physiology → mechanism of action → practice guide framework.
3. Adrenal Gland Therapies
The adrenal chapter covers several clinically important endocrine disorders, including
- Primary adrenal insufficiency
- Primary hyperaldosteronism
- Pheochromocytomas and other paraganglioma syndromes
- Classic congenital adrenal hyperplasia
- Nonclassic congenital adrenal hyperplasia
Therapeutic approaches include glucocorticoids, mineralocorticoids, androgens, mineralocorticoid antagonists, amiloride, alpha-blockers, beta-blockers, chemotherapy, metyrosine, MIBG, calcium channel blockers, insulin sensitizers, oral contraceptive pills, and antiandrogens.
The detailed treatment of Cushing’s disease provides a good example of the book's educational method. The discussion connects adrenal steroidogenesis with the enzymatic targets of metyrapone, mitotane, ketoconazole, and osilodrostat, while also discussing adverse effects and therapeutic monitoring.
4. Pancreatic Gland Therapies
Diabetes mellitus receives substantial attention in Chapter 4. The chapter covers insulin and numerous non-insulin therapies, including:
- Biguanides
- Meglitinides
- Sulfonylureas
- Dopaminergic agonists
- PPAR-gamma agonists
- GLP-1 agonists
- SGLT-2 inhibitors
- DPP-4 inhibitors
- Alpha-glucosidase inhibitors
- Amylin agonists
The chapter also extends beyond diabetes to include neuroendocrine tumors and hypoglycemia syndromes, with therapies such as telotristat, acid-lowering drugs, somatostatin analogs, diazoxide, diuretics, calcium channel blockers, mTOR inhibitors, and phenytoin.
5. Parathyroid Gland and Bone Therapies
Chapter 5 examines disorders involving calcium, parathyroid hormone, phosphate, and bone metabolism.
The major topics are:
- Primary hyperparathyroidism
- Hypoparathyroidism
- Paget’s disease of bone
- X-linked hypophosphatemia
- Osteoporosis
The book discusses calcimimetics, bisphosphonates, thiazide diuretics, active vitamin D, calcium, recombinant human PTH, calcitonin, phosphorus, burosumab, RANK-L inhibitors, PTH analogs, PTH-related protein analogs, anti-sclerostin inhibitors, selective estrogen receptor modulators, estrogen hormone replacement therapy, and calcium/vitamin D.
6. Reproductive Organ Therapies
The reproductive endocrinology chapter includes both female and male endocrine disorders.
Topics include:
- Polycystic ovary syndrome
- Male hypogonadism
- Menopause
- Turner’s syndrome
The PCOS section includes metformin, combined oral contraceptive pills, mineralocorticoid antagonists, gonadotropins, clomiphene citrate, letrozole, androgen receptor antagonists, finasteride, and weight-loss interventions.
Male hypogonadism is addressed through testosterone replacement, human chorionic gonadotropin, follicle-stimulating hormone, and clomiphene citrate. Menopause includes menopausal hormone therapy and SSRI/SNRI therapy, while Turner’s syndrome includes hormone replacement, metabolic therapies, and therapies related to linear growth.
7. Lipid Metabolism and Obesity
Chapter 7 focuses on disorders of lipid metabolism and obesity.
The hyperlipoproteinemia section discusses the following:
- Ezetimibe
- Statins
- PCSK9 inhibitors
- Omega-3 fatty acids
- Fibrates
- Inclisiran
- Niacin
The obesity section includes the following:
- Phentermine-topiramate
- Liraglutide
- Bupropion-naltrexone
- Intestinal lipase inhibitors
- Bariatric surgery
The chapter also addresses lipodystrophy syndromes, including insulin sensitizers and leptin.
8. Additional and Emerging Endocrine Topics
Chapter 8 provides a particularly broad collection of topics that extend beyond conventional gland-by-gland organization.
It discusses:
- Recent technological advances in diabetes care
- Insulin pumps
- Continuous glucose monitors
- Pumps and CGMs in practice
- Immune checkpoint inhibitor-related endocrinopathies
- Hypophysitis
- Thyroid dysfunction related to immune checkpoint inhibitors
- Autoimmune diabetes
- Hypoparathyroidism
- Pseudoendocrine conditions
- Adrenal fatigue
- Relative adrenal insufficiency
- Low T3 syndrome
- Hashimoto encephalopathy
- Drugs of abuse with endocrine side effects
The final subsection considers endocrine effects associated with cannabis, opioids, amphetamines, anabolic androgenic steroids, and selective estrogen receptor modulators.
9. Dynamic Tests in Clinical Endocrinology
Chapter 9 turns from pharmacotherapy toward dynamic endocrine testing.
The pituitary section includes:
- ACTH stimulation testing for adrenal insufficiency
- ACTH stimulation testing for nonclassic adrenal hyperplasia
- Dexamethasone suppression testing
- Glucagon stimulation testing
- Growth hormone suppression testing
- Water deprivation testing
- Inferior petrosal sinus sampling
- TRH stimulation testing
- GnRH stimulation testing
The thyroid section includes levothyroxine absorption testing and radioactive iodine scanning approaches in thyroid cancer. Adrenal testing includes oral sodium loading, intravenous saline suppression, clonidine suppression, insulin tolerance testing, and adrenal venous sampling.
Pancreatic testing includes oral glucose tolerance testing, the 72-hour fast, and secretin stimulation testing, while reproductive endocrinology includes the progestin challenge test.
Key Features
Several features distinguish the educational structure of endocrinology: Pathophysiology to Therapy:
- Integrated physiology and pharmacology: endocrine physiology is presented before mechanisms of therapy are examined.
- Mechanism-focused learning: therapies are explored through their physiological and pathophysiological targets.
- Clinical pharmacology pearls: the preface specifically highlights adverse effects and therapeutic monitoring.
- Practice guides: many therapeutic subsections are followed by practical guidance.
- Practice-based questions: chapters conclude with questions designed to reinforce application of the material.
- Landmark clinical trials: selected practice-changing trials are highlighted throughout the book.
- Broad endocrine coverage: nine chapters span major endocrine glands, metabolic disorders, reproductive endocrinology, obesity, and diagnostic testing.
- Dedicated dynamic-testing chapter: Diagnostic physiology receives a separate section rather than being treated only as an adjunct to therapy.
- Board-review material: the appendix includes common side effects of endocrine treatments and selected cardiovascular outcome trials in diabetes care.
- Medication reference material: an appendix provides brand names of common medications in several endocrine categories.
- Illustrations: the acknowledgments state that illustrations were created using Adobe InDesign and BioRender.
Who Should Read This Book
Medical Students
Medical students may find the physiology-first structure useful for connecting basic endocrine concepts with pharmacological treatment. Instead of learning individual medications in isolation, the book presents treatment in relation to endocrine pathways and mechanisms.
Residents
Internal medicine residents are specifically identified in the preface as part of the intended educational audience. The combination of physiology, mechanisms, clinical pharmacology pearls, practice guides, and practice-based questions can support endocrine learning during residency.
Endocrinology Specialists and Fellows
The book is particularly relevant to endocrinology fellows because the author emphasizes mechanisms of therapy and selected landmark clinical trials. The preface specifically states that endocrinology fellows and practicing physicians should be familiar with landmark trials in the field.
Researchers
Researchers and academically oriented clinicians may find the treatment-mechanism framework useful for reviewing the physiological rationale behind endocrine interventions. The book also contains bibliographical references throughout.
Exam Candidates
The presence of practice-based questions and an appendix specifically covering common side effects of endocrine treatments for board review makes the book potentially useful as a supplementary examination resource.
Why This Book is Useful
Clinical Relevance
One of the strongest aspects of the book is its attempt to connect physiology with clinical treatment. The author explains in the preface that the objective is not to provide an exhaustive account of endocrine pathophysiology but to help readers appreciate the rationale behind different therapies in clinically relevant terms.
This is particularly valuable in endocrinology, where understanding feedback loops, receptor activity, hormone synthesis, and signaling pathways can make treatment decisions easier to understand.
Evidence-Based Content
The book incorporates references and selected clinical-trial evidence. The appendix also identifies cardiovascular outcome trials involving GLP-1 agonists, SGLT-2 inhibitors, DPP-4 inhibitors, and other diabetes therapies, as well as landmark trials such as DCCT, EDIC, UKPDS, and ACCORD.
Practical Applications
The recurring Practice Guide sections provide a clinically oriented component. For example, the Cushing’s disease chapter discusses monitoring and adverse effects alongside mechanisms of treatment.
This structure encourages readers to move from
Physiology → Pathophysiology → Mechanism of action → Clinical considerations
That sequence can be particularly helpful when learning complex endocrine therapies.
Board Exam Usefulness
The book contains practice-based questions at the end of chapters and a board-review appendix addressing common side effects of endocrine treatments.
The book is therefore positioned not only as a conceptual textbook but also as a potentially useful supplementary review resource.
Learning Efficiency
The organization around specific endocrine disorders and individual treatment modalities can make targeted revision easier. A reader reviewing Cushing’s disease, for example, can move through several therapeutic mechanisms within the same section rather than searching across unrelated chapters.
Table of Contents Overview
The book contains nine main chapters, followed by an appendix and index:
1. Pituitary Gland Therapies- Cushing’s disease
- Acromegaly
- Prolactinoma
- Adult growth hormone insufficiency
- Central diabetes insipidus
- SIADH
2. Thyroid Gland Therapies
- Hashimoto’s thyroiditis
- Graves’ disease and thyroid eye disease
- Riedel’s thyroiditis
- Thyroid hormone resistance
- TSH-secreting tumors
- Thyroid cancer
3. Adrenal Gland Therapies
- Primary adrenal insufficiency
- Primary hyperaldosteronism
- Pheochromocytomas and paraganglioma syndromes
- Congenital adrenal hyperplasia
4. Pancreatic Gland Therapies
- Diabetes mellitus
- Neuroendocrine tumors
- Hypoglycemia syndromes
5. Parathyroid Gland and Bone Therapies
- Hyperparathyroidism
- Hypoparathyroidism
- Paget’s disease
- X-linked hypophosphatemia
- Osteoporosis
6. Reproductive Organ Therapies
- PCOS
- Male hypogonadism
- Menopause
- Turner’s syndrome
7. Therapies in Disorders of Lipid Metabolism and Obesity
- Hyperlipoproteinemia
- Obesity
- Lipodystrophy syndromes
8. Miscellaneous Topics in Disorders of Endocrine Glands
- Diabetes technology
- Immune checkpoint inhibitor-related endocrinopathies
- Pseudoendocrine conditions
- Endocrine effects of drugs of abuse
9. Dynamic Tests in Clinical Endocrinology
- Pituitary testing
- Thyroid testing
- Adrenal testing
- Pancreatic testing
- Reproductive endocrine testing
The appendices include cardiovascular outcome trials in diabetes care, common side effects of endocrine treatments for board review, and brand names of common endocrine medications.
Strengths of The Book
Based on the book's stated aims, organization, and contents, several academic strengths are apparent.
1. Strong mechanism-based framework
The most prominent strength is the consistent attempt to explain therapies through endocrine physiology. This can help readers develop conceptual understanding rather than relying entirely on memorization.
2. Broad specialty coverage
The nine chapters collectively address the major endocrine systems and extend into metabolic, reproductive, technological, toxicological, and diagnostic areas.
3. Clinical pharmacology emphasis
The preface specifically identifies side effects and therapeutic monitoring as important components of the text.
4. Inclusion of clinical trials
The book does not treat pharmacotherapy as purely theoretical. Selected landmark and practice-changing trials are highlighted, with a dedicated appendix of cardiovascular outcome trials in diabetes care.
5. Practice-oriented learning
Practice guides and practice-based questions are incorporated throughout the chapters. This provides a bridge between conceptual learning and clinical application.
6. Dedicated coverage of dynamic testing
The separate chapter on dynamic tests is a useful structural feature because endocrine diagnosis often depends on understanding physiological responses rather than relying solely on static laboratory measurements.
Limitations
The book itself acknowledges an important limitation: the first edition is not intended to provide exhaustive coverage of endocrine pathophysiology. The author explains that the focus is instead on the rationale behind therapies and their pathophysiological basis.
The preface also explains that the book deliberately avoids concentrating on guideline-defined treatment protocols, because endocrinology is a rapidly evolving area.
For readers seeking detailed, guideline-based management algorithms, this stated scope is therefore important to recognize.
Another practical consideration is that medical information can change as research, regulations, medications, and therapeutic recommendations evolve. The publisher's disclaimer explicitly advises readers to evaluate current prescribing information and relevant warnings for medicines, equipment, and devices.
Beyond these points, the available material does not provide a systematic independent assessment of the book's errors, omissions, readability, or comparative performance against other textbooks. It would therefore be inappropriate to make stronger negative judgments without additional evidence.
Comparison With Similar Books
Endocrinology: Pathophysiology to Therapy adopts a therapy-centered, mechanism-based approach. Its organization repeatedly links endocrine physiology with the mechanisms of medical intervention, while also incorporating clinical pharmacology pearls, practice questions, selected clinical trials, and dynamic testing.
Therefore, its distinctive educational emphasis is the relationship between pathophysiology and therapy, rather than an attempt to serve primarily as a comprehensive diagnostic or guideline manual.
FAQs
Endocrinology: Pathophysiology to Therapy is a first-edition endocrinology textbook by Akuffo Quarde, published in 2024. It focuses on integrating endocrine physiology with the mechanisms of medical therapies and includes clinical pharmacology considerations, practice-based questions, clinical trials, and dynamic endocrine testing.
The book is intended for endocrinology fellows, practicing physicians, internal medicine residents, medical students, pharmacists, nurse practitioners, physician assistants, and other allied healthcare professionals.
The primary specialty is endocrinology, with coverage of pituitary, thyroid, adrenal, pancreatic, parathyroid, bone, reproductive, lipid, obesity, and endocrine diagnostic disorders.
Yes. The pancreatic therapies chapter contains an extensive section on diabetes mellitus, including insulin, biguanides, meglitinides, sulfonylureas, GLP-1 agonists, SGLT-2 inhibitors, DPP-4 inhibitors, PPAR-gamma agonists, alpha-glucosidase inhibitors, amylin agonists, and other therapies.
Yes. Pharmacological mechanisms are central to the book's organization. The author describes an approach in which relevant physiology is followed by detailed mechanisms of action for selected medical interventions, with attention to clinical pharmacology pearls such as adverse effects and therapeutic monitoring.
The author specifically identifies medical students as an intended audience. Its physiology-to-mechanism structure and practice-based questions may support students who want to understand the rationale behind endocrine therapies rather than simply memorize treatment names.
Yes. Practice-based questions appear at the end of the major chapters, and the appendix includes material specifically described as board review.
Yes. Chapter 9 is dedicated to dynamic tests in clinical endocrinology and covers tests involving pituitary, thyroid, adrenal, pancreatic, and reproductive endocrine disorders.
Conclusion
Endocrinology: Pathophysiology to Therapy offers a clearly defined educational approach to endocrine medicine: understand the physiology, understand the pathophysiology, and then understand why a therapy works.
Its first-edition structure covers an unusually broad range of endocrine subjects, beginning with pituitary therapies and progressing through thyroid, adrenal, pancreatic, parathyroid and bone, reproductive, lipid, and obesity disorders. The book then expands into diabetes technology, immune checkpoint inhibitor-related endocrinopathies, pseudoendocrine conditions, endocrine effects of drugs of abuse, and dynamic endocrine testing.
For medical students and residents, the physiology-and-mechanism framework can provide a useful conceptual foundation.
For endocrinology fellows and practicing clinicians, the discussions of therapeutic mechanisms, clinical pharmacology pearls, practice guides, and selected landmark trials provide additional clinically oriented material. Pharmacists and other healthcare professionals are also explicitly included among the intended readers.
The book is not presented as an exhaustive endocrinology reference or a guideline-driven treatment manual. Instead, its strength lies in explaining the rationale behind endocrine therapies and connecting pharmacological interventions with underlying physiological pathways. That distinction is important when deciding how to use it alongside other clinical resources.
For readers looking for a structured way to connect endocrine physiology with pharmacotherapy, Endocrinology: Pathophysiology to Therapy provides a focused and clinically oriented learning framework.
Disclaimer
MedBook 4 Free does not own the copyrights to this video/book/software. We’re sharing this with our audience ONLY for educational purposes, and we strongly encourage visitors to purchase original, licensed software/books.
If someone with copyright wants us to remove this software/book, please contact us immediately. You can email [email protected] for all DMCA/removal requests.